Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Next Previous
X
Search
Trial Profile

A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms DIAMOND; DIAMOND 1
  • Sponsors Oculis Pharma

    • Most Recent Events

    • 21 Oct 2024 According to an Oculis Pharma media release, Substantial patient enrollment progress achieved since the end of Q2 2024 through early October, with ~70% of patients enrolled in this trial, company accelerates the patient enrollment and expansion of the DIAMOND program committees with globally renowned retina experts.
    • 15 Oct 2024 According to an Oculis Pharma media release, results with OCS-01 eye drops in DME from Stage 1 of the DIAMOND program (DIAMOND-1 and DIAMOND-2) at Week 12 and will present the design of Stage 2 to assess the efficacy and safety of OCS-01 eye drops for the treatment of DME at Week 52 will be presented at Eyecelerator 2024, ahead of the American Academy of Ophthalmology Annual Meeting.
    • 27 Aug 2024 According to an Oculis media release, patient enrollment through the end of June exceeded the Companys expectations and was at 35% and 23% for DIAMOND-1 and DIAMOND-2, respectively.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top